# Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lenvatinib-versus-sorafenib-as-first-line-therapy-of-advanced-hepatocellular/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Antonio Facciorusso,Nicola Tartaglia,Rosanna Villani,Gaetano Serviddio,Daryl Ramai,Babu P. Mohan,Saurabh Chandan,Mohamed A. Abd El Aziz,Jessica Evangelista,Christian Cotsoglou,Antonio Ambrosi |
| Citations | 75 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/8129234 |
| OpenAlex ID | https://openalex.org/W3161350039 |
| PMID | 34017396 |
| Type | review |
| Year | 2021 |

## Paper authors

- [Babu P. Mohan](https://scholariq.org/researchers/babu-p-mohan/)
- [Daryl Ramai](https://scholariq.org/researchers/daryl-ramai/)

## Paper journal

- [PubMed](https://scholariq.org/journals/pubmed/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Mechanisms and Therapy](https://scholariq.org/topics/cancer-mechanisms-and-therapy/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.